Oculis Partners with National MS Society to Accelerate…

Event summary

Oculis joins the National MS Society’s 5-year Campaign to End MS as the industry partner focusing on Vision, launching October 1, 2026.
Oculis is developing Privosegtor, a neuroprotective therapy for optic neuritis and acute MS relapses, with Breakthrough Therapy and PRIME designations.
The PIONEER program includes two registrational trials for optic neuritis and plans for an IND submission for acute MS relapses in Q4 2026.
Privosegtor has shown potential in preserving retinal ganglion cells and improving mobility in MS models.

The big picture

Oculis’s partnership with the National MS Society underscores the growing focus on neuroprotective therapies for MS, a condition affecting 2.8 million people worldwide. The collaboration aligns with broader industry trends toward accelerating research and improving patient outcomes, particularly in areas with significant unmet medical needs like optic neuritis and acute MS relapses. The strategic move positions Oculis to leverage its Privosegtor program, which has already received Breakthrough Therapy and PRIME designations, to potentially become the first neuroprotective therapy for these conditions.

What we're watching

Regulatory Progress: Whether Privosegtor’s IND submission for acute MS relapses in Q4 2026 will meet FDA expectations and advance smoothly.
Clinical Trial Outcomes: The pace at which the PIONEER program’s registrational trials for optic neuritis will yield results and support Privosegtor’s approval.
Market Potential: How Oculis’s partnership with the National MS Society will impact the company’s standing in the neuroprotective therapy space.